Lataa...
Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma
Improved knowledge about the pathogenesis of asthma has facilitated the development of novel drugs and provided hope for patients with severe asthma. After the short- and long-term success of omalizumab in severe allergic phenotype, researchers have targeted patients with severe eosinophilic asthma...
Tallennettuna:
| Julkaisussa: | Turk Thorac J |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Turkish Thoracic Society
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7020889/ https://ncbi.nlm.nih.gov/pubmed/32163366 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/TurkThoracJ.2019.180204 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|